Crinetics Pharmaceuticals Reports Definitive Merger Agreement with Vertex
Summary
On July 6, 2026, Crinetics Pharmaceuticals, Inc. entered into a definitive Agreement and Plan of Merger with Vertex Pharmaceuticals Incorporated and its subsidiary, Clark Merger Sub, Inc. Under the terms, Merger Sub will merge into Crinetics, with Crinetics becoming a wholly owned subsidiary of Vertex. Crinetics shareholders will receive $85.00 per share in cash for their common stock. Vertex held an investor conference call with a presentation (via Ex. 99.1), and a joint press release (via Ex. 99.2) was issued announcing the agreement.
Why It Matters
This merger agreement is highly material as it outlines the acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals for $85.00 per share in cash, converting Crinetics into a wholly owned subsidiary of Vertex. This represents a significant corporate transaction for Crinetics shareholders.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how VRTX traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View VRTX Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“00 per share in cash, without interest thereon and subject to applicable withholding taxes (the ".”
— From Item 1.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000875320
- Filing Date
- Tuesday, July 7, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral